Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

(RTTNews) - The European Commission has approved Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is indicated ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus ® (ocrelizumab) data and continued research into ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April ...

Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Please provide your email address to receive an email when new articles are posted on . Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated ...

A systematic review identified 15 studies, enabling a meta-analysis of 443 NMOSD patients with 639 pregnancies. Rates of pregnancy-related NMOSD relapses were highest during the first 3 months ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...